Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 59 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Norovirus Clear all

Conditions: Anogenital Herpes, COVID-19, Herpes Labialis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 120 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms
Interventions: MK-4830, Pembrolizumab, Carboplatin, Pemetrexed, Lenvatinib, Paclitaxel, Cisplatin, MK-4830A; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Detroit, Michigan • St Louis, Missouri + 6 more

Conditions: Breast Cancer
Interventions: Cyclophosphamide, Docetaxel, Doxorubicin, NOV 002; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Miami, Florida • Charleston, South Carolina

Conditions: Norovirus Infections
Interventions: VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T, VXA G2.4 NS-T; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: COVID-19
Interventions: No intervention; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 12,566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gastroenteritis Norovirus
Interventions: Placebo, Norwalk Virus; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Transplant Failure
Interventions: No investigational intervention performed for this study; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Ovarian Cancer
Interventions: NOV-002, Carboplatin; Drug
Lead sponsor: Cellectar Biosciences, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Acute Gastroenteritis
Interventions: Not listed
Lead sponsor: Luminex Corporation; Industry
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 2 more

Conditions: Norovirus Gastroenteritis
Interventions: VXA-G1.1-NN Oral Vaccine; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 19 Years to 49 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Gastroenteritis Norovirus
Interventions: Nitazoxanide, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 99 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 12
States / cities: Chicago, Illinois • Kansas City, Kansas • Baltimore, Maryland + 6 more

Conditions: Non Small Cell Lung Cancer
Interventions: Paclitaxel, NOV-002, Carboplatin; Drug
Lead sponsor: Cellectar Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 12
States / cities: Muscle Shoals, Alabama • San Diego, California • Chicago, Illinois + 9 more

Conditions: Norovirus Infections
Interventions: Donor Breastmilk; Dietary Supplement
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: NSCLC
Interventions: Imprime PGG Injection, Cetuximab, Paclitaxel, Carboplatin; Biological · Drug
Lead sponsor: HiberCell, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 5
States / cities: Augusta, Georgia • Terre Haute, Indiana • Minneapolis, Minnesota + 2 more

Conditions: Fibrostenotic Crohn's Disease
Interventions: Ontunisertib, Placebo; Drug
Lead sponsor: Agomab Spain S.L.U.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Sun City, Arizona • Bradenton, Florida • Albany, New York + 4 more

Conditions: Cellulite
Interventions: Soliton Rapid Acoustic Pulse (RAP); Device
Lead sponsor: Soliton; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Multiple Myeloma
Interventions: First-line therapy, Second-line Multiple Myeloma treatments; Other · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 3,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 252
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 211 more

Conditions: Gastroenteritis
Interventions: HIL-214; Biological
Lead sponsor: HilleVax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Rolling Hills Estates, California • Stockbridge, Georgia

Conditions: Low Grade Serous Ovarian Cancer
Interventions: avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 38
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Paclitaxel, Carboplatin, Ascorbic Acid; Drug
Lead sponsor: Joseph J. Cullen, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Non-Small Cell Lung Cancer
Interventions: Pembrolizumab SC, Pembrolizumab IV, Paclitaxel, Nab-Paclitaxel, Carboplatin, Cisplatin, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 18
States / cities: Jonesboro, Arkansas • Fullerton, California • Los Alamitos, California + 14 more

Conditions: Norovirus Infections
Interventions: VXA-GI.1.NN, Placebo Tablet; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Cypress, California • New Orleans, Louisiana • Austin, Texas

Conditions: Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin, Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, Topotecan, Gemcitabine; Biological · Drug
Lead sponsor: Mural Oncology, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 31 more

Conditions: Prevention From Norovirus Infection
Interventions: Norovirus Bivalent Vaccine, Saline Comparator; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Rochester, New York + 2 more

Search by objective public record fields.

Viral Infections in Healthy and Immunocompromised Hosts

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

COVID-19 & Psychiatry: A Retrospective Chart Review

New Challenge Pool of Norwalk Virus Inoculum

Intraoperative Echocardiographic Evaluation of Pulmonary Vein Velocities and Outcomes in Lung Transplantation

Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

NNITS-Nitazoxanide for Norovirus in Transplant Patients Study

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Human Breastmilk in Young Children With Norovirus Infection of the Gut

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) for the Treatment of Cellulite

Connect® MM- The Multiple Myeloma Disease Registry

Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Pharmacological Ascorbate for Lung Cancer

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Norovirus Bivalent-Vaccine Efficacy Study